Inkmaker Shanghai doubles size of factory to meet demand during Covid-19
Inkmaker Group announces that as of 7 April 2020 Inkmaker Shanghai will begin operating from a new 35,000 square feet facility, double the size of its current factory space, to meet with the demands due to the recent escalation in workload and orders.
The expansion, part of IM Group’s investment plan, started with the acquisitions of the businesses of Rexson Systems and Vale-Tech in the UK last October, and more recently those of Tecnopails in Italy. "We had originally planned for this expansion later in the year but, in view of the increased workload as a consequence of the Covid-19 situation, we have brought our plans forward to meet the demand head on,” said Kar Seng, General Manager of Inkmaker Shanghai and board member of the Inkmaker Group.
The move comes at a much needed moment for the group, which recently adapted to government recommendations in the most-at-risk countries where it is present, with most employees working in remote from home. "These are challenging times, but we are well placed to take full advantage of our investments: factories—not just representative agents—in different countries are ensuring we can quickly shift workorders and physically continue production to ensure deliveries are met,” said Roberto Guerra, CEO Asia, Inkmaker Group.
2026-09-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
POND GROUP Acquires All Grace, Boosting Cosmetics Market Share by 20%
-
Freudenberg Group acquires fastener coating enterprises
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
Recommend Reading
-
BASF Sells Coatings Business for €7.7 Billion, Forming Independent Company with Carlyle
-
Dow’s “Double Salvo”: Behind the €150/ton Hike, Europe’s Chemical Industry Is Being Strangled by a “Cost Noose”
-
Clariant Names Marcelo Lu as Heir Apparent in High-Stakes Leadership Handover for Care Chemicals
-
Huntsman’s Rotterdam MDI Line Stumbles—$10M EBITDA Hit Sends Q4 Guidance to the Low End
-
Saudi Arabia Flips the Switch on Jafurah: World’s Largest Non-U.S. Shale Gas Field Begins Production
-
Business Society: Formic Acid Price Center Moves Lower, Entering a Consolidation Phase
-
China's Marine Fuel Market Sees Volatile Rise in September
-
South Korea and Japan Launch Energy Supply Chain Cooperation as Hormuz Risks Grow
-
Crude oil remains in negative territory, another round of retail fuel price cuts in China
-
Formic Acid Prices Sideways; Future Plant Maintenance Plans Scheduled